Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Collaborative Medicinal Development Pty Limited
- Target Recruit Count
- 55
- Registration Number
- NCT04313166
- Locations
- 🇦🇺
Macquarie University, Macquarie Park, New South Wales, Australia
CuATSM Compared With Placebo for Treatment of ALS/MND
- First Posted Date
- 2019-09-09
- Last Posted Date
- 2019-11-06
- Lead Sponsor
- Collaborative Medicinal Development Pty Limited
- Target Recruit Count
- 80
- Registration Number
- NCT04082832
- Locations
- 🇦🇺
Macquarie University, Macquarie, New South Wales, Australia
Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- Collaborative Medicinal Development Pty Limited
- Target Recruit Count
- 31
- Registration Number
- NCT03204929
- Locations
- 🇦🇺
The Royal Melbourne Hospital, Melbourne, Victoria, Australia
🇦🇺Macquarie University, Macquarie Park, New South Wales, Australia
ALS Treatment Extension Study
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Collaborative Medicinal Development Pty Limited
- Target Recruit Count
- 28
- Registration Number
- NCT03136809
- Locations
- 🇦🇺
Macquarie University, Sydney, New South Wales, Australia
Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND
Phase 1
Completed
- Conditions
- Amyotrophic Lateral SclerosisMotor Neuron Disease
- Interventions
- First Posted Date
- 2016-08-17
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- Collaborative Medicinal Development Pty Limited
- Target Recruit Count
- 50
- Registration Number
- NCT02870634
- Locations
- 🇦🇺
Calvary Health Care Bethlehem, Caulfield, Victoria, Australia
🇦🇺Macquarie University, Sydenham, New South Wales, Australia
Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2019-02-21
- Lead Sponsor
- Collaborative Medicinal Development Pty Limited
- Target Recruit Count
- 14
- Registration Number
- NCT02688101
- Locations
- 🇦🇺
Monash Cancer Center, Melbourne, Victoria, Australia
🇦🇺Lifehouse Cancer Treatment Centre, Sydney, New South Wales, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
© Copyright 2025. All Rights Reserved by MedPath